First human test for experimental cancer antibody begins
NCT ID NCT06205706
Summary
This is a first-in-human trial testing a new drug called BI-1910, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have worsened after standard treatments. The main goals are to find a safe dose, check for side effects, and see early signs of whether the treatment might help shrink tumors. About 35 adults with cancers like lung or liver cancer will receive the drug by infusion every three weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HM Sanchinarro
Madrid, Spain
-
Hospital Fundacion Jimenez Diaz
Madrid, Spain
-
Hospital HM Nou Delfos
Barcelona, 08023, Spain
-
Hospital universitario Virgen del Rocio
Seville, Spain
-
Karolinska University Hospital, Solna
Stockholm, Sweden
-
Lund University Hospital
Lund, Sweden
-
Rigshospitalet
Copenhagen, Denmark
-
Universitätsklinikum Essen
Essen, Germany
Conditions
Explore the condition pages connected to this study.